Unusual presentation of rearranged metastatic non-small cell lung cancer.

Respir Med Case Rep

Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.

Published: August 2024

The spectrum of clinical and radiographic presentations of lung adenocarcinoma is increasingly broad, including in the metastatic setting. Here, we report on a patient who initially presented with a mild chronic cough that remained stable over a decade, with serial CT scans showing gradual worsening of multifocal areas of consolidation and ground-glass opacities of the bilateral lungs. The patient was ultimately diagnosed with rearranged lung adenocarcinoma and achieved a dramatic response with entrectinib. This case highlights the variable presentation of non-small cell lung cancer (NSCLC) and the importance of comprehensive molecular testing for newly diagnosed metastatic NSCLC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11386496PMC
http://dx.doi.org/10.1016/j.rmcr.2024.102091DOI Listing

Publication Analysis

Top Keywords

non-small cell
8
cell lung
8
lung cancer
8
lung adenocarcinoma
8
unusual presentation
4
presentation rearranged
4
rearranged metastatic
4
metastatic non-small
4
lung
4
cancer spectrum
4

Similar Publications

The CDKN2A gene, responsible for encoding the tumor suppressors p16(INK4A) and p14(ARF), is frequently inactivated in non-small cell lung cancer (NSCLC). Herein, an uncharacterized long non-coding RNA (lncRNA) (ENSG00000267053) on chromosome 19p13.12 was found to be overexpressed in NSCLC cells with an active, wild-type CDKN2A gene.

View Article and Find Full Text PDF

DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer.

Acta Pharm Sin B

December 2024

Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.

encodes a DNA methyltransferase involved in development, cell differentiation, and gene transcription, which is mutated and aberrant-expressed in cancers. Here, we revealed that loss of promotes malignant phenotypes in lung cancer. Based on the epigenetic inhibitor library synthetic lethal screening, we found that small-molecule HDAC6 inhibitors selectively killed -defective NSCLC cells.

View Article and Find Full Text PDF

To predict local progression after microwave ablation (MWA) in patients with stage I non-small cell lung cancer (NSCLC), we developed a CT-based radiomics model. Postoperative CT images were used. The intraclass correlation coefficients, two-sample t-test, least absolute shrinkage and selection operator (LASSO) regression, and Pearson correlation analysis were applied to select radiomics features and establish radiomics score.

View Article and Find Full Text PDF

EGFR and ALK are key driver mutations in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors are recommended as the first-line treatment for advanced NSCLC with driving oncogenes because they have fewer side effects and provide better disease control than chemotherapy. The present retrospective analysis aimed to investigate how altered driver genes impact cancer outcomes and clinical presentation.

View Article and Find Full Text PDF

Zerumbone is a sesquiterpene phytochemical with cytotoxic activity against cancer. This study aimed to evaluate the effect of zerumbone on cell viability by WST-1 test, apoptosis by TUNEL, lipid peroxidation markers (malondialdehyde, MDA, and 4-hydroxynonenal, HNE) by using assay kits, and biomolecular changes by ATR-FTIR spectroscopy in A549 cells. After zerumbone (0-100 μM) incubation for 24, 48, and 72 h, the number of TUNEL-positive cells was found to be higher in zerumbone-treated cells than in controls, in consistent with cell morphology results.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!